suPAR levels correlate with disease severity and survival rate of COVID-19 patients, representing a promising prognostic biomarker for the risk assessment of the disease.
By Nicolaj Toutain on Mon Sep 05 2022
category: News
Higher suPAR is associated with incident venous thromboembolism independently of D‐dimer in patients hospitalized for COVID‐19.
By ViroGates on Sat Aug 13 2022
The nonspecific prognostic biomarker suPAR successfully predicts all-cause 30-day mortality in all age groups.
By ViroGates on Tue Jun 21 2022
suPAR as a Prognostic Marker of Ugandan Children at Risk of Severe and Fatal Malaria
By ViroGates on Tue Jun 14 2022
Circulating suPAR associates with severity and in-hospital progression of COVID-19
By ViroGates on Wed May 04 2022
High blood sugar and suPAR levels independently worsen COVID-19 outcomes
By ViroGates on Tue Apr 19 2022
Soluble urokinase receptor and mortality in kidney transplant recipients
By ViroGates on Mon Feb 07 2022
Inflammation, hyperglycemia, and adverse outcomes in individuals with diabetes mellitus hospitalized for COVID-19
By ViroGates on Fri Feb 04 2022
Nature Medicine publication: Early anakinra treatment for COVID-19 guided by suPAR saves lives
By ViroGates on Tue Jan 11 2022
suPAR independently predicts severity and length of hospitalisation in patients with COVID-19
By ViroGates on Wed Dec 08 2021
900+
published suPAR studies in leading medical journals
The suPARnostic® brand consists of 3 products:
suPAR is used in clinical routine in 48 hospitals
48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.
New Webinar